We strive to overcome diseases through innovation and optimize medical treatment by humanized care so as to enable each individual enjoy the wonder of life.
We strive to overcome diseases through innovation and optimize medical treatment by humanized care so as to enable each individual enjoy the wonder of life.
As an international modern Chinese medicine enterprise, Tasly Pharma. (Stock code: 600535) is committed to developing into a leading solution provider of medicine and health services with global influence in China. With "people-oriented and precise innovation", Tasly Pharma. constantly promotes the progress of medicine and health to make every human-being can enjoy the beauty and hope of life.
Headquartered in Tianjin, China, the company has more than 20 research centers worldwide and 11 production bases throughout the country.We are committed to cracking the digital code of life medicine. Adhering to the concept of "patient-centered", we pay close attention to the evolution of disease spectrum, and make precise innovations in major therapeutic fields such as cardio-cerebrovascular, digestion and metabolism, tumor immunity, and neuroscience, which sustain the healthy life experience of human beings.
With a rich drug combination including modern Chinese medicine, chemical medicine and biological innovation medicine, regenerative medicine and the 4-D integrated health management solutions, we can provide service of the whole health journey including health examination, early warning, prevention, diagnosis, treatment and rehabilitation and a personalized and integrated medical solutions covering the whole disease course for each patient and family so as to meet the diverse needs of the individual life, optimize life experience and improve life quality.
We continue to build an integrated platform of the whole value chain of life health, explore and develop breakthrough therapies to solve unmet clinical needs, empower medical researchers, medical staff and industry partners, and bring multidisciplinary and interdisciplinary medical innovations to the benefit of patients around the world.
Our development proves that one research finding can give rise to an industry. Driven by the mission "people-oriented and precise R&D",we started from scratch and constantly forge ahead. Till present, we have made great achievements in the bio-pharmaceutical industry which benefit the whole world.
Tasly Joint Pharmaceutical Company, the predecessor of Tasly, was founded
The IND application of Compound Danshen Dripping Pill as a therapeutic drug was approved by FDA
Tasly (600535) was successfully listed on the Shanghai Stock Exchange
Tasly promoted its comprehensive internationalization layout
Compound Danshen Dripping Pill passed FDA Phase-II clinical trials
The construction of Tasly Huaian Biomedical Industrial Park started.
The “proUK”, a national Class-I new medicine for biological thromolysis, was launched in Shanghai
Tasly officially launched its operations in North America
Tasly established the State Key Laboratory of Core Technology in Innovative Chinese Medicine approved by The Ministry of Science and Technology of PRC
Tasly was approved by the National Development and Reform Commission to establish a State-local Joint Engineering Laboratory
Tasly was honored with MIIT's “National Model Enterprise for Industrial Brand Cultivation”
Tasly was honored with the 4th China Industrial Award
Tasly completed the FDA Phase III clinical trial for its Compound Danshen Dripping Pills
Tasly Holding Group held the flag-presenting ceremony for building of the start-up, backbone and career talent team
Tasly and the US-based drug maker Arbor signed an agreement on cooperation in the R&D and marketing of T89 (Compound Danshen Dripping Pills) in the United States
Tasly completed the layout of whole industrial line of stem cell
Compound Danshen Dripping Pill for the treatment of acute altitude syndrome is nearing completion of FDA phase Ⅱ clinical trial
The International TCM Sharing Platform was built for international academic exchanges and treatment of COVID-19 through cooperation
Xiaoyao Tablet was approved as a traditional botanical medicine of the European Union, which is the first Chinese compound Chinese medicine variety to pass the rug evaluation in Dutch
Compound Danshen Dripping Pill was approved to add new indications for diabetic retinopathy as 1.1 innovative Chinese medicine
Kunxinning Granule was declared and approved in the same year
Approved as "Science and Technology China" research and innovation base of modern TCM by the Ministry of Industry and Information Technology
Listed as Model Intelligent Manufacturing Factory of Modern TCM by National Ministry of Industry and Information
Won the Top 10 Outstanding Cases of intelligent technology innovation application in the 6th World Intelligence Congress
China Association of Chinese Medicine Science and Technology Award, Won Science and Technology Award - Policy Research Award of China Association of Chinese Medicine
Won the Group Award for Outstanding Contribution to Internationalization of TCM
• Ranked among the Top 100 Chinese Pharmaceutical Companies
• Ranked among the Top 20 Most Competitive Listed Chinese Pharmaceutical Companies for 11 consecutive years
• State-certified High-tech Company
• State-local Joint Engineering Laboratory in Advanced Manufacturing Technology of TCM
• Ranked among the Top 20 Chinese Pharmaceutical Groups in R&D
• State Key Laboratory of Core Technology in Innovative Chinese Medicine
• Ranked among Top 100 Chinese TCM Brands
• Ranked among Top 20 Listed Pharmaceutical Companies worthy of Investment
• Top 10 of Chinese Medicine Research and Development
• Nationwide Workers' Pioneer
• Contribution Award for TCM Internationalization
• Nationwide Cultured Youth Collectives
• Excellent Practice of Green and Low-carbon Development
• Responsible Enterprise for Anti-epidemic and Medicine Supply
• National Technology& Innovation Model Enterprise
Care for life, respect the laws of nature, increase life expectancy, and improve life quality.
We are committed to integrating medical achievements across various disciplines to meet the diverse needs of patients.
Build a smart digital network for health management, coordinate different products to ensure optimal efficacy at different disease stages, and maximize the value of the innovation ecosystem.
Utilize the Internet of Everything to create a full-life-cycle value chain for precise R&D, intelligent manufacturing, smart diagnosis and treatment, and whole-course management of diseases, to ensure continuous value empowerment.
Build a medical innovation and value co-creation system to empower medical workers, experts, and innovation partners.
At Tasly, we have integrated social responsibility into every aspect of our daily operations, and have built a sustainable development platform for the Great Health Industry to implement the 'Healthy China' campaign. We have aligned our corporate goals with what benefits social progress and people's health.
Quality assurance is not only primary responsibilities of an enterprise, but also the core of social responsibilities. Adhering to the quality-management concept of “quality originates from top-level design, and standard depends on precise execution,” we have adopted a comprehensive quality management model and have set up a plethora of quality management and testing methods that are in line with international standards. Quality assurance is implemented in design, R&D, production, marketing, and all other stages to ensure stable quality of drugs throughout the complete period.
Governance is not only a guarantee for the survival of an enterprise, but also a cornerstone for it to achieve sustained growth. We operate in accordance with applicable laws and regulations and ensure the stable and healthy development of the company in the capital market by improving our organizational structure and legal person governance system. We are committed to legal and regulatory compliance, integrity, and ethics in all our activities. We attach importance to investor relations, actively create value for shareholders, and do our best to protect the legitimate rights and interests of our shareholders and investors.
In the course of our development, we have consistently laid emphasis on low-carbon operations, energy conservation, environmental protection, and ecological development. We implement an environment-friendly, safe, healthy, and standardized energy management system that prevents and controls environmental pollution. We actively participate in environmental-protection activities to make the Earth a cleaner, better place to live in. In November 2018, our outstanding contributions to ‘green’ development, ecological conservation, and environmental protection, put us on the National Green Factory Demonstration List. We are one of the first companies in the pharmaceutical industry to receive this honor.
